Background and Purpose-The Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST) established guidelines to increase safety in acute stroke thrombolysis, but precluding treatment in an important proportion of patients. We aimed to assess safety/efficacy of thrombolysis in patients with SITS-MOST exclusion criteria. Methods-369 nonlacunar tPA-treated patients were studied. Patients were classified as SITS-MOST (SM) or non-SITS-MOST (NSM) according to SITS-MOST-criteria fulfilling. Clinical evaluation was assessed by NIHSS and functional outcome by mRS at 3 months (functional independencyϭmRS Յ2). 
T he Safe Implementation of Thrombolysis in StrokeMonitoring Study (SITS-MOST) was an observational study aimed to evaluate safety of tPA in clinical practice. 1 It showed similar or even better results than a pool of previous randomized trials, however using very strict patient selection criteria. 1 We hypothesize that these criteria could preclude treatment in an important proportion of patients, and designed a study to evaluate safety and efficacy of thrombolysis outside SITS-MOST.
Patients and Methods
Two retrospective groups were established from our prospective thrombolysis-database.: the SITS-MOST (SM) group and the Non-SITS-MOST (NSM) group.
SITS-MOST Group
Patients fulfilling published SITS-MOST criteria 1 (during the recruitment period, patients were also included in the SITS-MOST registry) were classified as SM.
Non-SITS-MOST Group
Not fulfilling-patients were subsequentially evaluated according to our institutional preestablished protocol, approved by the local ethic committee, and treated with tPA after informed-consent signature. Requirements included : (1) documented intracranial occlusion; (2) Ͻ6 hours stroke with mismatch on multiparametric MRI 2 ; (3) International Normalized Ratio (INR) Ͻ1.8; (4) Age, clinical stroke severity, or Diabetes Mellitus and previous symptomatic stroke (DMϩstroke) were not contraindications; (5) other tPA-contraindications (Ͼ6-hour time window, recent stroke, extent lesion on neuroimaging, severe comorbidity/disability) constituted exclusion from treatment and from the study.
To make more comparable both groups, only clinical nonlacunar strokes with a documented intracranial arterial occlusion were included.
Outcomes
Outcomes included: Primary, symptomatic intracranial hemorrhage (SICH); Secondary, recanalization, short-term evolution, and functional outcome.
Clinical/Vascular Evaluation
Stroke severity was sequentially assessed by the National Institute of Health Stroke Scale(NIHSS), defining: deterioration, increase of Ն4points or in-hospital death; improvement, decrease of Ն4points or complete recovery.
Functional outcome was evaluated by modified Rankin score (mRS) at 3 months (functional independency: mRS Յ2 3 ).
Arterial occlusion and recanalization were determined by TCD 4 performed before tPA-bolus and continuously during 2 hours. MRA was used to evaluate arterial occlusion on insufficient temporal windows.
Neuroimaging Evaluation
Evaluation consisted of: Ͻ3 hours (and 40 [32%] patients in the 3 to 6 hours with unavailable MRI), conventional CT-scan criteria 5 ; 3 to 6 hours, intracranial occlusionϩDWI/PWI mismatch Ͼ50% on multiparametric-MRI-protocol. 2 Intracranial hemorrhage was evaluated on 24-to 36-hour CT scan. 5 SICH was defined as "any hemorrhage with any decline in neurological status (NINDS)" 6 and "local/remote parenchymal hemorrhage with NIHSS increase Ն4points, or lethal(SITS-MOST Figure) .
The different outcomes of subgroups in NSM are shown in the Figure. When we excluded patients Ͼ80 years in the NSM-group, the functional outcome was similar to those fulfilling SITS-MOST (mRS Յ2 in NSM Ͻ80 years: 45.8%, Pϭ0.410). In a logistic regression model, the only predictors of worse functional outcome in NSM patients were higher baseline NIHSS and a proximal occlusion on TCD (PϽ0.05).
Discussion
This study shows that systemic thrombolysis can be safe in terms of intracranial hemorrhage in patients not-fulfilling SITS-MOST criteria. Recanalization and early clinical evolution were comparable. Long-term outcome and mortality tended to be worse in NSM, without reaching statistical significance. If patients older than 80 years were excluded from NSM, functional outcome was similar to SM-patients.
Our protocol was designed to explore safety/efficacy of more flexible criteria in agreement with the existing literature, 2,7,9 aiming to increase thrombolysis candidates. It allowed tPA treatment in Ͼ50% of our patients.
Main not-fulfilled criteria were age and time-window. Previous studies have suggested safety of tPA in Ͼ80 years in terms of SICH, with slightly worse functional outcome and mortality, 8 probably because comorbidity or complications. An exclusion criterion based on previous functional/morbidity state instead of raw age seems more rational.
Our MRI-selected Ͼ3 hours patients showed similar SICH and clinical outcomes to Ͻ3-hour time-window, in concordance with reports based on ischemic penumbra identification. 2, 9 Parenchymal injury selection rather than preset clock time-window could be considered.
The study has some limitations. Only patients with documented arterial occlusion were included, probably causing our high baseline NIHSS. Our results are thus not extensible to cohorts without vascular-occlusion selection. Furthermore, we did continuous TCD-monitoring; the enhancing effect of ultrasound on thrombolysis 10 could have influenced our data. We did not precalculate the sample size necessary to detect differences, and only included 369 patients. NSM-patients tended to higher mortality and worse long-term outcome, which could reach statistical significance increasing sample size.
This study does not pretend to modify thrombolysis guidelines but to open the debate and promote research. 
